Table 1. Results of broad-range (Round 1) dose ranging infection study.
| TDF Conc. (nM) | Dosing/infection Route | FTC Conc. (nM) | Dosing/infection Route | ||
|---|---|---|---|---|---|
| Vaginal | Rectal | Vaginal | Rectal | ||
| 8 | 0% (0/6) | 0% (0/6) | 1 | 0% (0/6) | 0% (0/6) |
| 80 | 0% (0/6) | 0% (0/6) | 10 | 0% (0/6) | 0% (0/6) |
| 800 | 0% (0/6) | 0% (0/6) | 100 | 0% (0/6) | 50% (3/6) |
| 8,000 | 67% (4/6) | 50% (3/6) | 1,000 | 50% (3/6) | 100% (6/6) |
| 80,000 | 100% (6/6) | 100% (6/6) | 10,000 | 100% (6/6) | 100% (6/6) |
Increasing concentrations of TDF or FTC were applied vaginally or rectally to humanized BLT mice (group of 6). After 15 min, mice were vaginally or rectally challenged with HIV and infection analyzed over a period of 12 weeks. Data are expressed as % of protection.